

=> d his ful

FILE 'HCAPLUS' ENTERED AT 11:51:40 ON 04 JUN 2004

E PRIESTLEY E SCOTT/AU

L1 18 SEA ABB=ON "PRIESTLEY E SCOTT"/AU
E DECICCO CARL P/AUL2 123 SEA ABB=ON ("DECICCO C P"/AU OR "DECICCO CARL"/AU OR "DECICCO
CARL P"/AU OR "DECICCO CARL PETER"/AU)L3 4 SEA ABB=ON L1 AND L2
SELECT RN L3 1-4

FILE 'REGISTRY' ENTERED AT 11:53:10 ON 04 JUN 2004

L4 221 SEA ABB=ON (149885-80-3/BI OR 18680-27-8/BI OR 103-71-9/BI OR
106-95-6/BI OR 108-98-5/BI OR 1149-26-4/BI OR 119479-32-2/BI
OR 124-63-0/BI OR 126689-01-8/BI OR 130653-09-7/BI OR 131357-48
-7/BI OR 131433-93-7/BI OR 13734-41-3/BI OR 146949-07-7/BI OR
15028-39-4/BI OR 1623-93-4/BI OR 17193-39-4/BI OR 172096-96-7/B
I OR 1730-25-2/BI OR 1899-93-0/BI OR 274918-51-3/BI OR
3182-79-4/BI OR 319009-74-0/BI OR 319009-76-2/BI OR 319009-78-4
/BI OR 319009-80-8/BI OR 319009-82-0/BI OR 319009-90-0/BI OR
319009-92-2/BI OR 319009-94-4/BI OR 319009-96-6/BI OR 319009-98
-8/BI OR 319010-99-6/BI OR 319011-02-4/BI OR 319011-08-0/BI OR
319011-10-4/BI OR 319011-16-0/BI OR 319011-18-2/BI OR 319011-22
-8/BI OR 319011-25-1/BI OR 319011-27-3/BI OR 319011-29-5/BI OR
323196-84-5/BI OR 323196-85-6/BI OR 323196-86-7/BI OR 323196-87
-8/BI OR 323196-88-9/BI OR 323196-89-0/BI OR 323196-90-3/BI OR
323196-91-4/BI OR 323196-92-5/BI OR 323196-93-6/BI OR 323196-94
-7/BI OR 323196-95-8/BI OR 323196-96-9/BI OR 323196-97-0/BI OR
323196-98-1/BI OR 323196-99-2/BI OR 323197-00-8/BI OR 323197-01
-9/BI OR 323197-02-0/BI OR 323197-03-1/BI OR 323197-04-2/BI OR
323197-05-3/BI OR 323197-06-4/BI OR 323197-07-5/BI OR 323197-08
-6/BI OR 323197-09-7/BI OR 323197-10-0/BI OR 323197-11-1/BI OR
323197-12-2/BI OR 323197-13-3/BI OR 323197-14-4/BI OR 323197-15
-5/BI OR 323197-16-6/BI OR 323197-17-7/BI OR 323197-18-8/BI OR
323197-19-9/BI OR 323197-20-2/BI OR 323197-21-3/BI OR 323197-22
-4/BI OR 323197-23-5/BI OR 323197-24-6/BI OR 323197-25-7/BI OR
323197-26-8/BI OR 323197-27-9/BI OR 323197-28-0/BI OR 323197-29
-1/BI OR 323197-30-4/BI OR 323197-31-5/BI OR 323197-32-6/BI OR
323197-33-7/BI OR 323197-34-8/BI OR 323197-35-9/BI OR 323197-36
-0/BI OR 323197-37-1/BI OR 323197-38-2/BI OR 323197-39-3/BI OR
323197-40-6/BI OR 323197-41-7/BI OR 323197-42-8/BI OR 323197-43
-9/BI OR 323197-44-0/BI OR 323197-45-1/BI OR 323197-46-2/BI OR
323197-47-3/BI OR 323197-48-4/BI OR 323197-58-6/BI OR 323197-73
-5/BI OR 323197-74-6/BI OR 359-07-9/BI OR 38329-34-9/BI OR
42918-86-5/BI OR 4333-56-6/BI OR 460-

FILE 'HCAPLUS' ENTERED AT 11:53:53 ON 04 JUN 2004

L5 4 SEA ABB=ON L3 AND L4

FILE 'REGISTRY' ENTERED AT 12:11:45 ON 04 JUN 2004

L6 STR

L7 0 SEA SSS SAM L6

L8 1 SEA SSS FUL L6

L9 STR L6

L10 0 SEA SSS SAM L9

FILE 'HCAPLUS' ENTERED AT 12:22:40 ON 04 JUN 2004

L11 2 SEA ABB=ON L8

Lukton 10/010,184


04/06/2004

L12 FILE 'CAOLD' ENTERED AT 12:49:26 ON 04 JUN 2004
0 SEA ABB=ON L8 *O from CA Old*

=> d que stat l11

L6

STR



REP G1=(1-3) CH2

VAR G2=H/C

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE


L8 1 SEA FILE=REGISTRY SSS FUL L6

L11 2 SEA FILE=HCAPLUS ABB=ON L8

=> d ibib abs hitstr l11 1-2

L11 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:23525 HCAPLUS
 DOCUMENT NUMBER: 138:90078
 TITLE: Preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease.
 INVENTOR(S): Priestley, E. Scott; Decicco, Carl P.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 45 pp., Cont.-in-part of U.S. Ser. No. 626,286, abandoned.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003008828	A1	20030109	US 2001-10184	20011206
PRIORITY APPLN. INFO.:			US 1999-145631P	P 19990726
			US 2000-626286	B2 20000725
OTHER SOURCE(S):			MARPAT 138:90078	
GI				



AB Title compds. I [X = B(OH)₂, BY₁Y₂, COCONHR_{1a}; Y₁, Y₂ = OH, F, amino, alkoxy; BY₁Y₂ = atoms to form a cyclic boron ester, amide, or amide-ester containing 2-20 C atoms and optionally 1-3 N, O, or S atoms; R₁, R_{1a} = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl; R₂ = H; R₁R₂C = cycloalkyl; R₃ = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, Ph, naphthyl, heteroaryl; R₄ = H, (substituted) alkyl, Ph, PhCH₂, PhCH₂CH₂; R₅ = H, QR_{5a}; Q = chain of 0-3 amino acids; R_{5a} = SOR₆, SO₂R₆, COR₆, CO₂R₈, etc.; R₆ = (substituted) alkyl, Ph, naphthyl, PhCH₂, heteroaryl; R₈ = alkyl, PhCH₂, cycloalkylmethyl; Z = (CH₂)₁₋₃] were prepared as inhibitors of hepatitis C virus NS3 protease. Thus, (1R)-1-[[[(2S)-3-cyclohexyl-2-[3-isopropyl-3-[[[(2S)-3-methyl-2-[(2-pyrazinylcarbonyl)amino]butanoyl]amino]-2-oxo-1-pyrrolidinyl]propanoyl]amino]-3-butenylboronic acid (+)-pinanediol ester was prepared by solution phase chemical A number of I inhibited hepatitis C virus NS3 protease with K_i <60 μM.

IT **323196-93-6P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease)

RN 323196-93-6 HCAPLUS

CN Boronic acid, [(1R)-1-[[[(2S)-3-cyclohexyl-2-[3-(1-methylethyl)-3-[[[(3-


methylphenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:78359 HCAPLUS
 DOCUMENT NUMBER: 134:147855
 TITLE: Preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease.
 INVENTOR(S): Priestley, E. Scott; Decicco, Carl P.
 PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
 SOURCE: PCT Int. Appl., 130 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007407	A1	20010201	WO 2000-US20189	20000726
W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1206449	A1	20020522	EP 2000-950642	20000726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRIORITY APPLN. INFO.:			US 1999-145631P	P 19990726
			WO 2000-US20189	W 20000726
OTHER SOURCE(S):			MARPAT 134:147855	
GI				



AB Title compds. [I; X = B(OH)₂, BYY1, COCONHR1a; Y1, Y2 = OH, F, amino, alkoxy; BYY1Y2 = atoms to form a cyclic boron ester, amide, or amide-ester containing 2-20 C atoms and optionally 1-3 N, O, or S atoms; R1, R1a = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl; R2 = H; R1R2C = cycloalkyl; R3 = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, Ph, naphthyl, heteroaryl; R4 = H, (substituted) alkyl, Ph, PhCH₂, PhCH₂CH₂; R5 = H, QR5a; Q = chain of 0-3 amino acids; R5a = SOR6, SO2R7, COR6, CO2R8; R6 = (substituted) alkyl, Ph, naphthyl, PhCH₂, heteroaryl; R7 = H, alkyl; R8 = alkyl, PhCH₂, cycloalkylmethyl; Q = (CH₂)₁₋₃], were prepared Thus, (1R)-1-[[[(2S)-3-cyclohexyl-2-[3-isopropyl-3-[[[(2S)-3-methyl-2-[(2-pyrazinylcarbonyl)amino]butanoyl]amino]-2-oxo-1-pyrrolidinyl]propanoyl]amino]-3-butenylboronic acid (+)-pinanediol ester was prepared by solution phase chemical A number of I inhibited hepatitis C virus

NS3 protease with Ki<60 μM.

IT **323196-93-6P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease)

RN 323196-93-6 HCAPLUS

CN Boronic acid, [(1R)-1-[[[(2S)-3-cyclohexyl-2-[3-(1-methylethyl)-3-[[[(3-methylphenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:


12

THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr l5 1-4

L5 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:23525 HCAPLUS
 DOCUMENT NUMBER: 138:90078
 TITLE: Preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease.
 INVENTOR(S): Priestley, E. Scott; Decicco, Carl P.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 45 pp., Cont.-in-part of U.S. Ser. No. 626,286, abandoned.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003008828	A1	20030109	US 2001-10184	20011206
PRIORITY APPLN. INFO.:			US 1999-145631P	P 19990726
			US 2000-626286	B2 20000725
OTHER SOURCE(S):			MARPAT 138:90078	
GI				



AB Title compds. I [X = B(OH)₂, BY₁Y₂, COCONHR_{1a}; Y₁, Y₂ = OH, F, amino, alkoxy; BY₁Y₂ = atoms to form a cyclic boron ester, amide, or amide-ester containing 2-20 C atoms and optionally 1-3 N, O, or S atoms; R₁, R_{1a} = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl; R₂ = H; R₁R₂C = cycloalkyl; R₃ = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, Ph, naphthyl, heteroaryl; R₄ = H, (substituted) alkyl, Ph, PhCH₂, PhCH₂CH₂; R₅ = H, QR_{5a}; Q = chain of 0-3 amino acids; R_{5a} = SOR₆, SO₂R₆, COR₆, CO₂R₈, etc.; R₆ = (substituted) alkyl, Ph, naphthyl, PhCH₂, heteroaryl; R₈ = alkyl, PhCH₂, cycloalkylmethyl; Z = (CH₂)₁₋₃] were prepared as inhibitors of hepatitis C virus NS3 protease. Thus, (1R)-1-[[[(2S)-3-cyclohexyl-2-[3-isopropyl-3-[[[(2S)-3-methyl-2-[(2-pyrazinylcarbonyl)amino]butanoyl]amino]-2-oxo-1-pyrrolidinyl]propanoyl]amino]-3-butenylboronic acid (+)-pinanediol ester was prepared by solution phase chemical A number of I inhibited hepatitis C virus NS3 protease with K_i <60 μM.

IT **149885-80-3**
 RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
 (inhibitors; preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease)
 RN 149885-80-3 HCAPLUS
 CN Proteinase, polyprotein-processing, NS3 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 323196-84-5P 323196-85-6P 323196-86-7P
 323196-87-8P 323196-88-9P 323196-89-0P
 323196-90-3P 323196-91-4P 323196-92-5P
 323196-93-6P 323196-94-7P 323196-95-8P
 323196-96-9P 323196-97-0P 323196-98-1P
 323196-99-2P 323197-00-8P 323197-01-9P
 323197-02-0P 323197-03-1P 323197-04-2P
 323197-05-3P 323197-06-4P 323197-07-5P
 323197-08-6P 323197-09-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C
 virus NS3 protease)

RN 323196-84-5 HCAPLUS

CN Pyrazinecarboxamide, N-[(1S)-1-[[[1-[(1S)-1-(cyclohexylmethyl)-2-[(1R)-1-
 [(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-
 benzodioxaborol-2-yl]-3-butenyl]amino]-2-oxoethyl]-3-(1-methylethyl)-2-oxo-
 3-pyrrolidinyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323196-85-6 HCAPLUS

CN Pyrazinecarboxamide, N-[(1S)-1-[[[1-[(1S)-1-(cyclohexylmethyl)-2-[(1R)-1-
 [(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-
 benzodioxaborol-2-yl]-3-butenyl]amino]-2-oxoethyl]-3-(1-methylethyl)-2-oxo-
 3-piperidinyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323196-86-7 HCAPLUS


CN 1H-Azepine-1-acetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-
 trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]hexahydro-3-
 [(methylsulfonyl)amino]-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-87-8 HCAPLUS
 CN 1-Pyrrolidineacetamide, 3-amino- α -(cyclohexylmethyl)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-, monohydrochloride, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 323196-88-9 HCAPLUS
 CN 1-Pyrrolidineacetamide, 3-[[[1,1'-biphenyl]-4-ylsulfonyl]amino]- α -(cyclohexylmethyl)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323196-89-0 HCAPLUS

CN 1-Pyrrolidineacetamide, α -(cyclohexylmethyl)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-3-[(4-phenylphenyl)sulfonyl]amino]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323196-90-3 HCAPLUS


CN 1-Pyrrolidineacetamide, α -(cyclohexylmethyl)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-3-[(1-naphthalenylsulfonyl)amino]-2-oxo-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323196-91-4 HCAPLUS
 CN 1-Pyrrolidineacetamide, α -(cyclohexylmethyl)-N-[(1R)-1-
 [(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-
 benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-3-
 [[(phenylamino)carbonyl]amino]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323196-92-5 HCAPLUS
 CN 1-Pyrrolidineacetamide, α -(cyclohexylmethyl)-N-[(1R)-1-
 [(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-
 benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-3-[[3-
 methylphenyl)sulfonyl]amino]-2-oxo-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-93-6 HCAPLUS
 CN Boronic acid, [(1R)-1-[[2S)-3-cyclohexyl-2-[3-(1-methylethyl)-3-[[3-
 methylphenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-
 oxopropyl]amino]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323196-94-7 HCAPLUS

CN Carbamic acid, [1-[(1S)-2-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxo-1-phenylethyl]-3-(1-methylethyl)-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323196-95-8 HCAPLUS

CN 1-Pyrrolidineacetamide, 3-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo- α -phenyl-, monohydrochloride, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 323196-96-9 HCAPLUS
 CN 1-Pyrrolidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-3-[(methylsulfonyl)amino]-2-oxo-α-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-97-0 HCAPLUS
 CN 1-Pyrrolidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-α-phenyl-3-[[4-propylphenyl)sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323196-98-1 HCAPLUS
 CN Carbamic acid, [1-[(1S)-1-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-

trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]carbonyl]-3-methylbutyl]-3-(1-methylethyl)-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323196-99-2 HCAPLUS

CN 1-Pyrrolidineacetamide, 3-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)- α -(2-methylpropyl)-2-oxo-, monohydrochloride,
(α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 323197-00-8 HCAPLUS

CN 1-Pyrrolidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)- α -(2-methylpropyl)-3-[(methylsulfonyl)amino]-2-oxo-, (α S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-01-9 HCAPLUS

CN 1-Pyrrolidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)- α -(2-methylpropyl)-2-oxo-3-[(4-propylphenyl)sulfonyl]amino]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-02-0 HCAPLUS

CN Pyrazinecarboxamide, N-[(1S)-1-[[[1-[(1S)-1-(cyclohexylmethyl)-2-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-butenyl]amino]-2-oxoethyl]-3-ethyl-2-oxo-3-pyrrolidinyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323197-03-1 HCAPLUS

CN Carbamic acid, [1-[(1S)-1-(cyclohexylmethyl)-2-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxoethyl]-3-(1-methylethyl)-2-oxo-3-piperidinyl]-, (9CI) (CA INDEX NAME)

phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-04-2 HCAPLUS

CN Carbamic acid, [1-[(1S)-2-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxo-1-phenylethyl]-3-(1-methylethyl)-2-oxo-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-05-3 HCAPLUS

CN 1-Piperidineacetamide, 3-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo- α -phenyl-, monohydrochloride, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 323197-06-4 HCAPLUS

CN Carbamic acid, [1-[(1S)-2-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxo-1-phenylethyl]-3-(1-methylethyl)-2-oxo-3-piperidinyl]-, methyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 323197-07-5 HCAPLUS

CN 1-Piperidineacetamide, 3-(benzoylamino)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo- α -phenyl-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-08-6 HCAPLUS


CN 1-Piperidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-3-[(methylsulfonyl)amino]-2-oxo- α -phenyl-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323197-09-7 HCAPLUS
 CN 1-Piperidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-3-[[[(3-methylphenyl)sulfonyl]amino]-2-oxo- α -phenyl-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 85-46-1, 1-Naphthylsulfonyl chloride 98-88-4, Benzoyl chloride 103-71-9, Phenyl isocyanate, reactions 106-95-6, Allyl bromide, reactions 108-98-5, Thiophenol, reactions 124-63-0, Methanesulfonyl chloride 359-07-9 460-37-7, 3,3,3-Trifluoropropyl iodide 931-59-9, Phenylsulfonyl chloride 1149-26-4 1623-93-4, 4-Biphenylsulfonyl chloride 1730-25-2, Allylmagnesium bromide 1899-93-0 3182-79-4 4333-56-6, Cyclopropyl bromide 6009-07-0 13734-41-3 15028-39-4, L-Phenylglycine methyl ester hydrochloride 17193-39-4 18680-27-8 38329-34-9, L-Phenylglycine hydrochloride 42918-86-5 76347-13-2 84110-32-7 90084-27-8 119479-32-2 130653-09-7 146949-07-7 323197-58-6 323197-73-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease)


RN 85-46-1 HCAPLUS
 CN 1-Naphthalenesulfonyl chloride (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 98-88-4 HCAPLUS
 CN Benzoyl chloride (8CI, 9CI) (CA INDEX NAME)




RN 103-71-9 HCAPLUS
 CN Benzene, isocyanato- (9CI) (CA INDEX NAME)




RN 106-95-6 HCAPLUS
 CN 1-Propene, 3-bromo- (9CI) (CA INDEX NAME)




RN 108-98-5 HCAPLUS
 CN Benzenethiol (8CI, 9CI) (CA INDEX NAME)




RN 124-63-0 HCAPLUS
 CN Methanesulfonyl chloride (6CI, 8CI, 9CI) (CA INDEX NAME)




RN 359-07-9 HCAPLUS
 CN Ethane, 2-bromo-1,1-difluoro- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 460-37-7 HCAPLUS
 CN Propane, 1,1,1-trifluoro-3-iodo- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 931-59-9 HCAPLUS
 CN Benzenesulfonyl chloride (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 1149-26-4 HCAPLUS
 CN L-Valine, N-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).




RN 1623-93-4 HCAPLUS
 CN [1,1'-Biphenyl]-4-sulfonyl chloride (9CI) (CA INDEX NAME)




RN 1730-25-2 HCAPLUS
 CN Magnesium, bromo-2-propenyl- (9CI) (CA INDEX NAME)




RN 1899-93-0 HCAPLUS
 CN Benzenesulfonyl chloride, 3-methyl- (9CI) (CA INDEX NAME)



RN 3182-79-4 HCAPLUS
 CN Glycine, N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 4333-56-6 HCAPLUS
 CN Cyclopropane, bromo- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 6009-07-0 HCAPLUS
 CN Disulfide, chloro phenyl (8CI, 9CI) (CA INDEX NAME)

PhS - S - Cl


RN 13734-41-3 HCAPLUS
 CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 15028-39-4 HCAPLUS
 CN Benzeneacetic acid, α -amino-, methyl ester, hydrochloride,
 (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



● HCl

RN 17193-39-4 HCAPLUS
 CN Cyclohexanepropanoic acid, α -amino-, methyl ester, hydrochloride,
 (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



● HCl


RN 18680-27-8 HCAPLUS
 CN Bicyclo[3.1.1]heptane-2,3-diol, 2,6,6-trimethyl-, (1S,2S,3R,5S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 38329-34-9 HCAPLUS
 CN Benzeneacetic acid, α -amino-, hydrochloride, (α S)- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry. Rotation (+).



● HCl


RN 42918-86-5 HCAPLUS
 CN Butanoic acid, 2-[[(phenylmethoxy)carbonyl]amino]-, (2S)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry. Rotation (-).



RN 76347-13-2 HCAPLUS


CN 1,3,2-Dioxaborolane, 4,4,5,5-tetramethyl-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 84110-32-7 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole, 2-ethenylhexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 90084-27-8 HCAPLUS


CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[(1S)-1-chloro-2-(phenylmethoxy)ethyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 119479-32-2 HCAPLUS

CN 4-Pentenoic acid, 2-[[[(1,1-dimethylethoxy)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 130653-09-7 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole, 2-(1-chloroethenyl)hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)



RN 146949-07-7 HCAPLUS


CN Benzenesulfonyl chloride, 4-propyl- (9CI) (CA INDEX NAME)



RN 323197-58-6 HCAPLUS

CN L-Valine, N-(pyrazinylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-73-5 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-trimethyl- α -2-propenyl-, (α R,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 66080-23-7P 66866-64-6P 70557-99-2P
 83622-42-8P 94242-86-1P 95656-94-3P
 126689-01-8P 131357-48-7P 131433-93-7P
 172096-96-7P 319009-74-0P 319009-76-2P
 319009-78-4P 319009-80-8P 319009-82-0P
 319009-90-0P 319009-92-2P 319009-94-4P
 319009-96-6P 319009-98-8P 319010-99-6P
 319011-02-4P 319011-08-0P 319011-10-4P
 319011-16-0P 319011-18-2P 319011-22-8P
 319011-25-1P 319011-27-3P 319011-29-5P
 323197-10-0P 323197-11-1P 323197-12-2P
 323197-13-3P 323197-14-4P 323197-15-5P
 323197-16-6P 323197-17-7P 323197-18-8P
 323197-19-9P 323197-20-2P 323197-21-3P
 323197-22-4P 323197-23-5P 323197-24-6P
 323197-25-7P 323197-26-8P 323197-27-9P
 323197-28-0P 323197-29-1P 323197-30-4P
 323197-31-5P 323197-32-6P 323197-33-7P
 323197-34-8P 323197-35-9P 323197-36-0P
 323197-37-1P 323197-38-2P 323197-39-3P
 323197-40-6P 323197-41-7P 323197-42-8P
 323197-43-9P 323197-44-0P 323197-45-1P
 323197-46-2P 323197-47-3P 323197-48-4P
 323197-74-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C
 virus NS3 protease)

RN 66080-23-7 HCAPLUS


CN 1,3,2-Dioxaborolane, 4,4,5,5-tetramethyl-2-[(phenylthio)methyl]- (9CI)
 (CA INDEX NAME)



RN 66866-64-6 HCAPLUS

CN 3-Oxazolidinecarboxylic acid, 4-(1-methylethyl)-5-oxo-, phenylmethyl
 ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 70557-99-2 HCAPLUS


CN 1,3,2-Dioxaborolane, 2-(iodomethyl)-4,4,5,5-tetramethyl- (9CI) (CA INDEX

NAME)




RN 83622-42-8 HCAPLUS

CN 1,3,2-Dioxaborolane, 2-(chloromethyl)-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 94242-86-1 HCAPLUS


CN 1,3,2-Dioxaborolane, 2-(1-chloroethyl)-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 95656-94-3 HCAPLUS


CN 3-Oxazolidinecarboxylic acid, 4-ethyl-5-oxo-, phenylmethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 126689-01-8 HCAPLUS


CN 1,3,2-Dioxaborolane, 2-cyclopropyl-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 131357-48-7 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[(1S)-1-chloro-3-butenyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 131433-93-7 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole, hexahydro-3a,5,5-trimethyl-2-(2-propenyl)-, (3aS,4S,6S,7aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172096-96-7 HCAPLUS

CN 3-Oxazolidinecarboxylic acid, 4-(1-methylethyl)-5-oxo-, 1,1-dimethylethyl ester, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 319009-74-0 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-

trimethyl- α -[1-(phenylmethoxy)ethyl]-, hydrochloride,
 (α R,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 319009-76-2 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-trimethyl- α -[(phenylmethoxy)methyl]-, hydrochloride,
 (α R,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 319009-78-4 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-trimethyl- α -[(phenylthio)methyl]-, hydrochloride, (3aS,4S,6S,7aR)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 319009-80-8 HCAPLUS


CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-trimethyl-α-[(phenyldithio)methyl]-, (3aS,4S,6S,7aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 319009-82-0 HCAPLUS


CN 1,3,2-Dioxaborolane-2-methanamine, 4,4,5,5-tetramethyl-α-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)



RN 319009-90-0 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-trimethyl-α-2-propenyl-, hydrochloride, (αR,3aS,4S,6S,7aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 319009-92-2 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, α -ethylhexahydro-3a,5,5-trimethyl-, hydrochloride, (α R,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 319009-94-4 HCAPLUS

CN 1,3,2-Dioxaborolane-2-methanamine, α -cyclopropyl-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 319009-96-6 HCAPLUS


CN 1,3,2-Dioxaborolane-2-methanamine, α -(2,2-difluoroethyl)-4,4,5,5-tetramethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 319009-98-8 HCAPLUS
 CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, α -ethenylhexahydro-3a,5,5-trimethyl-, hydrochloride, (α R,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 319010-99-6 HCAPLUS
 CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[(1S)-1-chloropropyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 319011-02-4 HCAPLUS
 CN 1,3,2-Dioxaborolane, 2-(chlorocyclopropylmethyl)-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)




RN 319011-08-0 HCAPLUS

CN 1,3,2-Dioxaborolane, 2-[3,3-difluoro-1-(phenylthio)propyl]-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 319011-10-4 HCAPLUS


CN 1,3,2-Dioxaborolane, 2-(3,3-difluoro-1-iodopropyl)-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 319011-16-0 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole, hexahydro-3a,5,5-trimethyl-2-[1-(phenylmethoxy)ethyl]-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 319011-18-2 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[(1S)-1-chloro-2-(phenylmethoxy)propyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 319011-22-8 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[1-chloro-2-(phenylthio)ethyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 319011-25-1 HCAPLUS


CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[1-chloro-2-(phenyldithio)ethyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 319011-27-3 HCAPLUS

CN 1,3,2-Dioxaborolane, 4,4,5,5-tetramethyl-2-[4,4,4-trifluoro-1-(phenylthio)butyl]- (9CI) (CA INDEX NAME)




RN 319011-29-5 HCAPLUS

CN 1,3,2-Dioxaborolane, 4,4,5,5-tetramethyl-2-(4,4,4-trifluoro-1-iodobutyl)-
(9CI) (CA INDEX NAME)




RN 323197-10-0 HCAPLUS

CN 3-Oxazolidinecarboxylic acid, 4-(1-methylethyl)-5-oxo-4-(2-propenyl)-,
phenylmethyl ester (9CI) (CA INDEX NAME)




RN 323197-11-1 HCAPLUS

CN 4-Pentenoic acid, 2-(1-methylethyl)-2-[[(phenylmethoxy) carbonyl] amino]-,
methyl ester (9CI) (CA INDEX NAME)



RN 323197-12-2 HCAPLUS


CN Valine, 2-(2-oxoethyl)-N-[(phenylmethoxy) carbonyl]-, methyl ester (9CI)
(CA INDEX NAME)



RN 323197-13-3 HCAPLUS

CN 1-Pyrrolidineacetic acid, α -(cyclohexylmethyl)-3-(1-methylethyl)-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, (α S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 323197-14-4 HCAPLUS

CN 1-Pyrrolidineacetic acid, 3-amino- α -(cyclohexylmethyl)-3-(1-methylethyl)-2-oxo-, methyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-15-5 HCAPLUS

CN 1-Pyrrolidineacetic acid, α -(cyclohexylmethyl)-3-(1-methylethyl)-3-[[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-, methyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-16-6 HCAPLUS


CN 1-Pyrrolidineacetic acid, α-(cyclohexylmethyl)-3-(1-methylethyl)-3-
[[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-,
(αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323197-17-7 HCAPLUS

CN Norvaline, 5-hydroxy-2-(1-methylethyl)-N-[(phenylmethoxy)carbonyl]-,
methyl ester (9CI) (CA INDEX NAME)



RN 323197-18-8 HCAPLUS


CN Norvaline, 2-(1-methylethyl)-5-oxo-N-[(phenylmethoxy)carbonyl]-, methyl
ester (9CI) (CA INDEX NAME)



RN 323197-19-9 HCAPLUS

CN Cyclohexanepropanoic acid, α -[[4-(methoxycarbonyl)-5-methyl-4-
 [(phenylmethoxy)carbonyl]amino]hexyl]amino]-, methyl ester, (α S)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-20-2 HCAPLUS

CN 1-Piperidineacetic acid, α -(cyclohexylmethyl)-3-(1-methylethyl)-2-
 oxo-3-[[[(phenylmethoxy)carbonyl]amino]amino]-, methyl ester, (α S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-21-3 HCAPLUS

CN 1-Piperidineacetic acid, 3-amino- α -(cyclohexylmethyl)-3-(1-
 methylethyl)-2-oxo-, methyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-22-4 HCAPLUS

CN 1-Piperidineacetic acid, α -(cyclohexylmethyl)-3-(1-methylethyl)-3-
 [[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-,
 methyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-23-5 HCAPLUS


CN 1-Piperidineacetic acid, α -(cyclohexylmethyl)-3-(1-methylethyl)-3-
 [[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-,
 (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323197-24-6 HCAPLUS

CN Glycine, 4,5-didehydro-N-[(1,1-dimethylethoxy)carbonyl]norvalyl-N-2-
 propenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 323197-25-7 HCAPLUS

CN 1H-Azepine-1-acetic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2,3,4,7-tetrahydro-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 323197-26-8 HCAPLUS


CN 1H-Azepine-1-acetic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2,3,4,7-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



RN 323197-27-9 HCAPLUS

CN Carbamic acid, [1-[2-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxoethyl]hexahydro-2-oxo-1H-azepin-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323197-28-0 HCAPLUS

CN 1H-Azepine-1-acetamide, 3-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]hexahydro-2-

oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-29-1 HCAPLUS

CN 1-Pyrrolidineacetic acid, α-(cyclohexylmethyl)-3-(1-methylethyl)-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-30-4 HCAPLUS

CN Carbamic acid, [1-[(1S)-1-(cyclohexylmethyl)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxoethyl]-3-(1-methylethyl)-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-31-5 HCAPLUS

CN 1-Pyrrolidineacetic acid, 3-(1-methylethyl)-2-oxo-α-phenyl-3-
[[[(phenylmethoxy)carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-32-6 HCAPLUS


CN 1-Pyrrolidineacetic acid, 3-(1-methylethyl)-α-(2-methylpropyl)-2-oxo-
3-[[[(phenylmethoxy)carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323197-33-7 HCAPLUS

CN 3-Oxazolidinecarboxylic acid, 4-ethyl-5-oxo-4-(2-propenyl)-, phenylmethyl
ester (9CI) (CA INDEX NAME)




RN 323197-34-8 HCAPLUS

CN 4-Pentenoic acid, 2-ethyl-2-[[(phenylmethoxy) carbonyl] amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 323197-35-9 HCAPLUS


CN Butanoic acid, 2-ethyl-4-oxo-2-[[(phenylmethoxy) carbonyl] amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 323197-36-0 HCAPLUS

CN 1-Pyrrolidineacetic acid, α -(cyclohexylmethyl)-3-ethyl-2-oxo-3-[[(phenylmethoxy) carbonyl] amino]-, methyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-37-1 HCAPLUS

CN 1-Pyrrolidineacetic acid, 3-amino- α -(cyclohexylmethyl)-3-ethyl-2-oxo-, methyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-38-2 HCAPLUS


CN 1-Pyrrolidineacetic acid, α -(cyclohexylmethyl)-3-ethyl-3-[[[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-, methyl ester, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323197-39-3 HCAPLUS
 CN 1-Pyrrolidineacetic acid, α -(cyclohexylmethyl)-3-ethyl-3-[[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 323197-40-6 HCAPLUS
 CN 3-Oxazolidinecarboxylic acid, 4-(1-methylethyl)-5-oxo-4-(2-propenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 323197-41-7 HCAPLUS
 CN 4-Pentenoic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 323197-42-8 HCAPLUS
 CN 4-Pentenoic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-2-(1-methylethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 323197-43-9 HCAPLUS

CN Norvaline, N-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-2-(1-methylethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 323197-44-0 HCAPLUS


CN Norvaline, N-[(1,1-dimethylethoxy)carbonyl]-2-(1-methylethyl)-5-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 323197-45-1 HCAPLUS


CN Benzeneacetic acid, α -[[4-[[[(1,1-dimethylethoxy)carbonyl]amino]-5-methyl-4-[(phenylmethoxy)carbonyl]hexyl]amino]-, methyl ester, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323197-46-2 HCAPLUS
 CN Benzeneacetic acid, α -[[4-carboxy-4-[[[1,1-dimethylethoxy)carbonyl]amino]-5-methylhexyl]amino]-, monomethyl ester, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323197-47-3 HCAPLUS
 CN 1-Piperidineacetic acid, 3-[[[1,1-dimethylethoxy)carbonyl]amino]-3-(1-methylethyl)-2-oxo- α -phenyl-, methyl ester, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323197-48-4 HCAPLUS
 CN 1-Piperidineacetic acid, 3-[[[1,1-dimethylethoxy)carbonyl]amino]-3-(1-methylethyl)-2-oxo- α -phenyl-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-74-6 HCAPLUS
 CN 1-Pyrrolidineacetic acid, 3-(1-methylethyl)-2-oxo- α -phenyl-3-[[[phenylmethoxy)carbonyl]amino]-, methyl ester, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 483387-26-4 483387-27-5 483387-28-6
483387-29-7

RL: PRP (Properties)

(unclaimed protein sequence; preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease.)

RN 483387-26-4 HCAPLUS

CN Peptide, (Asp-Glu-Xaa-Glu-Xaa-Cys) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 483387-27-5 HCAPLUS

CN Peptide, (Asp-Xaa-Ile-Val-Pro-Cys) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 483387-28-6 HCAPLUS

CN Peptide, (Asp-Glu-Val-Val-Pro-Xaa) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 483387-29-7 HCAPLUS

CN Peptide, (Asp-Glu-Asp-Glu-Glu-Xaa-Ala-Ser-Lys) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 204765-53-7 438493-18-6 483340-48-3
483340-49-4

RL: PRP (Properties)


(unclaimed sequence; preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease.)

RN 204765-53-7 HCAPLUS


CN L-Lysine, L-lysyl-L-lysylglycyl-L-seryl-L-valyl-L-valyl-L-isoleucyl-L-valylglycyl-L-arginyl-L-isoleucyl-L-valyl-L-leucyl-L-serylglycyl-L-lysyl-L-prolyl-L-alanyl-L-isoleucyl-L-isoleucyl-L-prolyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 1-B



PAGE 1-C




PAGE 2-D




RN 438493-18-6 HCAPLUS
 CN L-Histidine, L-methionyl-L-arginylglycyl-L-seryl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-methionylglycyl-L-alanyl-L-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C



RN 483340-48-3 HCAPLUS

CN L-Histidine, L-methionylglycyl-L-alanyl-L-glutaminyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 483340-49-4 HCAPLUS

CN L-Cysteine, L- α -aspartyl-L- α -glutamyl-L- α -glutamyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:767330 HCAPLUS

DOCUMENT NUMBER: 138:221813

TITLE: P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease

AUTHOR(S): **Priestley, E. Scott**; De Lucca, Indawati; Ghavimi, Bahman; Erickson-Viitanen, Susan; **Decicco, Carl P.**

CORPORATE SOURCE: Experimental Station, Bristol-Myers Squibb Pharmaceutical Research Institute, Wilmington, DE, 19880-0500, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(21), 3199-3202

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of peptide boronic acids containing extended, hydrophobic P1 residues was prepared to probe the shallow, hydrophobic S1 region of HCV NS3 protease. The p-trifluoromethylphenethyl P1 substituent was identified as

optimal with respect to inhibitor potency for NS3 and selectivity against elastase and chymotrypsin.

IT 9004-06-2, Elastase 9004-07-3, Chymotrypsin
149885-80-3, Ns3 protease

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of P1 phenethyl peptide boronic acid inhibitors of HCV NS3 protease)

RN 9004-06-2 HCAPLUS

CN Elastase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9004-07-3 HCAPLUS

CN Chymotrypsin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 149885-80-3 HCAPLUS

CN Proteinase, polyprotein-processing, NS3 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 500763-17-7P 500763-19-9P 500763-21-3P

500763-23-5P 500763-25-7P 500763-27-9P

500763-29-1P 500763-31-5P 500763-33-7P

500763-35-9P 500763-37-1P 500763-39-3P

500763-42-8P 500763-44-0P 500763-46-2P

500763-48-4P 500763-50-8P 500763-52-0P

500763-53-1P 500763-55-3P 500763-57-5P

500763-59-7P 500763-61-1P 500763-63-3P

500763-65-5P 500763-67-7P 500763-69-9P

500763-71-3P 500763-73-5P 500763-74-6P

500763-75-7P 500763-76-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)

(preparation of P1 phenethyl peptide boronic acid inhibitors of HCV NS3 protease)

RN 500763-17-7 HCAPLUS

CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-
benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 500763-19-9 HCAPLUS

CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
 [(1R)-1-[(3aS,4S,6S,7aR)-3a-butylhexahydro-5,5-dimethyl-4,6-methano-1,3,2-
 benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 500763-21-3 HCAPLUS

CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
 [(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-pentyl-4,6-methano-
 1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 500763-23-5 HCAPLUS

CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
 [(1R)-1-[(3aS,4S,6S,7aR)-3a-hexylhexahydro-5,5-dimethyl-4,6-methano-1,3,2-
 benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 500763-25-7 HCAPLUS

CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-(2-methylpropyl)-4,6-
methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 500763-27-9 HCAPLUS

CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-(3-methylbutyl)-4,6-
methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 500763-29-1 HCAPLUS

CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-(4-methylpentyl)-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 500763-31-5 HCAPLUS

CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
[(1R)-1-[(3aR,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-phenyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 500763-33-7 HCAPLUS

CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-(phenylmethyl)-4,6-
methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 500763-35-9 HCAPLUS

CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-(2-phenylethyl)-4,6-
methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 500763-37-1 HCAPLUS

CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-(3-phenylpropyl)-4,6-
methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 500763-39-3 HCAPLUS

CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-(4-phenylbutyl)-4,6-
methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 500763-42-8 HCAPLUS

CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-[2-(2-
methylphenyl)ethyl]-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 500763-44-0 HCAPLUS

CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-[2-(3-
methylphenyl)ethyl]-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 500763-46-2 HCAPLUS

CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
 [(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-[2-(4-
 methylphenyl)ethyl]-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 500763-48-4 HCAPLUS
 CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
 [(1R)-1-[(3aS,4S,6S,7aR)-3a-[2-(2,4-dimethylphenyl)ethyl]hexahydro-5,5-
 dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 500763-50-8 HCAPLUS
 CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
 [(1R)-1-[(3aS,4S,6S,7aR)-3a-[2-(2,5-dimethylphenyl)ethyl]hexahydro-5,5-
 dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 500763-52-0 HCAPLUS

CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
[(1R)-1-[(3aS,4S,6S,7aR)-3a-[2-(2-fluorophenyl)ethyl]hexahydro-5,5-
dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 500763-53-1 HCAPLUS

CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
[(1R)-1-[(3aS,4S,6S,7aR)-3a-[2-(3-fluorophenyl)ethyl]hexahydro-5,5-

dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500763-55-3 HCAPLUS

CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-3a-[2-(4-fluorophenyl)ethyl]hexahydro-5,5-dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

|
 F

RN 500763-57-5 HCAPLUS
 CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
 [(1R)-1-[(3aS,4S,6S,7aR)-3a-[2-(2,6-difluorophenyl)ethyl]hexahydro-5,5-
 dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 500763-59-7 HCAPLUS

CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-[2-[3-
(trifluoromethyl)phenyl]ethyl]-4,6-methano-1,3,2-benzodioxaborol-2-
yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500763-61-1 HCAPLUS

CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-[2-[4-

(trifluoromethyl)phenyl]ethyl]-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

CF3

RN 500763-63-3 HCAPLUS
 CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
 [(1R)-1-[(3aS,4S,6S,7aR)-3a-[2-(4-chlorophenyl)ethyl]hexahydro-5,5-
 dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 500763-65-5 HCAPLUS
 CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
 [(1R)-1-[(3aS,4S,6S,7aR)-3a-[2-(4-bromophenyl)ethyl]hexahydro-5,5-dimethyl-
 4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

Br

RN 500763-67-7 HCAPLUS
 CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
 [(1R)-1-[(3aS,4S,6S,7aR)-3a-(2-[1,1'-biphenyl]-4-ylethyl)hexahydro-5,5-
 dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

Ph

RN 500763-69-9 HCAPLUS
 CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
 [(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-[2-[4-(1-
 methylethyl)phenyl]ethyl]-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

i-Pr


RN 500763-71-3 HCAPLUS
 CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
 [(1R)-1-[(3aS,4S,6S,7aR)-3a-[2-(4-cyclohexylphenyl)ethyl]hexahydro-5,5-
 dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 500763-73-5 HCAPLUS
 CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
 [(1R)-1-[(3aS,4S,6S,7aR)-3a-[2-[4-(1,1-dimethylethyl)phenyl]ethyl]hexahydro-5,5-dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

t-Bu

RN 500763-74-6 HCAPLUS
 CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
 [(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a-[2-(4-hydroxyphenyl)ethyl]-5,5-
 dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 500763-75-7 HCAPLUS
 CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
 [(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a-[2-(4-methoxyphenyl)ethyl]-5,5-
 dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

|
 OMe

RN 500763-76-8 HCAPLUS
 CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-
 [(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-[2-(4-
 phenoxyphenyl)ethyl]-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A


OPh

IT 98-80-6, Phenylboronic acid 100-58-3, Phenylmagnesium bromide 100-80-1, 3 Methylstyrene 350-51-6, 3 Fluorostyrene 394-46-7, 2 Fluorostyrene 402-24-4, 3 Trifluoromethylstyrene 402-50-6, 4 Trifluoromethylstyrene 405-99-2, 4 Fluorostyrene 611-15-4, 2 Methylstyrene 622-97-9, 4 Methylstyrene 637-69-4, 4 Methoxystyrene 693-03-8, Butylmagnesium bromide 693-25-4, Pentylmagnesium bromide 925-90-6, Ethylmagnesium bromide 926-62-5, Isobutylmagnesium bromide 1073-67-2, 4 Chlorostyrene 1462-75-5 1589-82-8, Benzylmagnesium bromide 1746-23-2, 4 tert Butylstyrene 2039-82-9, 4 Bromostyrene 2039-89-6, 2 5 Dimethylstyrene 2055-40-5, 4 Isopropylstyrene 2146-67-0, Dichloromethyl lithium 2234-20-0, 2 4 Dimethylstyrene 2350-89-2, 4 Phenylstyrene 2628-17-3, 4 Hydroxystyrene 3277-89-2, Phenethylmagnesium bromide 3761-92-0, Hexylmagnesium bromide 4548-78-1, Isopentylmagnesium bromide 4973-29-9, 4 Phenoxy styrene 5419-55-6, Triisopropyl borate 7429-94-9, 4-Methylpentylmagnesium bromide 13020-34-3, 4 Cyclohexylstyrene 18680-27-8 27152-04-1 207226-37-7, 2 6 Difluorostyrene 274918-51-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of P1 phenethyl peptide boronic acid inhibitors of HCV NS3 protease)


RN 98-80-6 HCAPLUS
CN Boronic acid, phenyl- (9CI) (CA INDEX NAME)




RN 100-58-3 HCAPLUS
CN Magnesium, bromophenyl- (8CI, 9CI) (CA INDEX NAME)




RN 100-80-1 HCAPLUS
CN Benzene, 1-ethenyl-3-methyl- (9CI) (CA INDEX NAME)




RN 350-51-6 HCAPLUS
CN Benzene, 1-ethenyl-3-fluoro- (9CI) (CA INDEX NAME)




RN 394-46-7 HCAPLUS
CN Benzene, 1-ethenyl-2-fluoro- (9CI) (CA INDEX NAME)




RN 402-24-4 HCAPLUS
CN Benzene, 1-ethenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 402-50-6 HCAPLUS
CN Benzene, 1-ethenyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 405-99-2 HCAPLUS
CN Benzene, 1-ethenyl-4-fluoro- (9CI) (CA INDEX NAME)




RN 611-15-4 HCAPLUS
CN Benzene, 1-ethenyl-2-methyl- (9CI) (CA INDEX NAME)



RN 622-97-9 HCAPLUS
CN Benzene, 1-ethenyl-4-methyl- (9CI) (CA INDEX NAME)




RN 637-69-4 HCAPLUS
CN Benzene, 1-ethenyl-4-methoxy- (9CI) (CA INDEX NAME)




RN 693-03-8 HCAPLUS
CN Magnesium, bromobutyl- (8CI, 9CI) (CA INDEX NAME)

n-Bu-Mg-Br


RN 693-25-4 HCAPLUS
CN Magnesium, bromopentyl- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 925-90-6 HCAPLUS
CN Magnesium, bromoethyl- (8CI, 9CI) (CA INDEX NAME)




RN 926-62-5 HCAPLUS
CN Magnesium, bromo(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 1073-67-2 HCAPLUS
CN Benzene, 1-chloro-4-ethenyl- (9CI) (CA INDEX NAME)




RN 1462-75-5 HCAPLUS
CN Magnesium, bromo(3-phenylpropyl)- (8CI, 9CI) (CA INDEX NAME)




RN 1589-82-8 HCAPLUS
CN Magnesium, bromo(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 1746-23-2 HCAPLUS
CN Benzene, 1-(1,1-dimethylethyl)-4-ethenyl- (9CI) (CA INDEX NAME)




RN 2039-82-9 HCAPLUS
CN Benzene, 1-bromo-4-ethenyl- (9CI) (CA INDEX NAME)




RN 2039-89-6 HCAPLUS
CN Benzene, 2-ethenyl-1,4-dimethyl- (9CI) (CA INDEX NAME)




RN 2055-40-5 HCAPLUS
CN Benzene, 1-ethenyl-4-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 2146-67-0 HCAPLUS
CN Lithium, (dichloromethyl)- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 2234-20-0 HCAPLUS
CN Benzene, 1-ethenyl-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 2350-89-2 HCAPLUS
CN 1,1'-Biphenyl, 4-ethenyl- (9CI) (CA INDEX NAME)




RN 2628-17-3 HCAPLUS
CN Phenol, 4-ethenyl- (9CI) (CA INDEX NAME)




RN 3277-89-2 HCAPLUS
CN Magnesium, bromo(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 3761-92-0 HCAPLUS
CN Magnesium, bromohexyl- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 4548-78-1 HCAPLUS
CN Magnesium, bromo(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 4973-29-9 HCAPLUS
CN Benzene, 1-ethenyl-4-phenoxy- (9CI) (CA INDEX NAME)




RN 5419-55-6 HCAPLUS
CN Boric acid (H₃BO₃), tris(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 7429-94-9 HCAPLUS

CN Magnesium, bromo(4-methylpentyl)- (9CI) (CA INDEX NAME)



RN 13020-34-3 HCAPLUS


CN Benzene, 1-cyclohexyl-4-ethenyl- (9CI) (CA INDEX NAME)



RN 18680-27-8 HCAPLUS


CN Bicyclo[3.1.1]heptane-2,3-diol, 2,6,6-trimethyl-, (1S,2S,3R,5S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 27152-04-1 HCAPLUS

CN Magnesium, bromo(4-phenylbutyl)- (8CI, 9CI) (CA INDEX NAME)



RN 207226-37-7 HCAPLUS


CN Benzene, 2-ethenyl-1,3-difluoro- (9CI) (CA INDEX NAME)



RN 274918-51-3 HCAPLUS

CN L-Proline, N-[(1,1-dimethylethoxy)carbonyl]-L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:78359 HCAPLUS

DOCUMENT NUMBER: 134:147855

TITLE: Preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease.

INVENTOR(S): **Priestley, E. Scott; Decicco, Carl P.**

PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 130 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007407	A1	20010201	WO 2000-US20189	20000726
W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1206449	A1	20020522	EP 2000-950642	20000726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: US 1999-145631P P 19990726
WO 2000-US20189 W 20000726

OTHER SOURCE(S): MARPAT 134:147855
GI



AB Title compds. [I; X = B(OH)₂, BYY1, COCONHR1a; Y1, Y2 = OH, F, amino, alkoxy; BYY1Y2 = atoms to form a cyclic boron ester, amide, or amide-ester containing 2-20 C atoms and optionally 1-3 N, O, or S atoms; R1, R1a = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl; R2 = H; R1R2C = cycloalkyl; R3 = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, Ph, naphthyl, heteroaryl; R4 = H, (substituted) alkyl, Ph, PhCH₂, PhCH₂CH₂; R5 = H, QR5a; Q = chain of 0-3 amino acids; R5a = SOR6, SO2R7, COR6, CO2R8; R6 = (substituted) alkyl, Ph, naphthyl, PhCH₂, heteroaryl; R7 = H, alkyl; R8 = alkyl, PhCH₂, cycloalkylmethyl; Q = (CH₂)₁₋₃], were prepared Thus, (1R)-1-[[[(2S)-3-cyclohexyl-2-[3-isopropyl-3-[[[(2S)-3-methyl-2-[(2-pyrazinylcarbonyl)amino]butanoyl]amino]-2-oxo-1-pyrrolidinyl]propanoyl]amino]-3-butenylboronic acid (+)-pinanediol ester was prepared by solution phase chemical A number of I inhibited hepatitis C virus

NS3 protease with Ki<60 μM.

IT **149885-80-3**

RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)

(inhibitors; preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease)

RN 149885-80-3 HCAPLUS

CN Proteinase, polyprotein-processing, NS3 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **323196-84-5P 323196-85-6P 323196-86-7P**
323196-87-8P 323196-88-9P 323196-89-0P
323196-90-3P 323196-91-4P 323196-92-5P
323196-93-6P 323196-94-7P 323196-95-8P
323196-96-9P 323196-97-0P 323196-98-1P
323196-99-2P 323197-00-8P 323197-01-9P
323197-02-0P 323197-03-1P 323197-04-2P
323197-05-3P 323197-06-4P 323197-07-5P
323197-08-6P 323197-09-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease)

RN 323196-84-5 HCAPLUS

CN Pyrazinecarboxamide, N-[(1S)-1-[[[1-[(1S)-1-(cyclohexylmethyl)-2-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-butenyl]amino]-2-oxoethyl]-3-(1-methylethyl)-2-oxo-3-pyrrolidinyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323196-85-6 HCAPLUS

CN Pyrazinecarboxamide, N-[(1S)-1-[[[1-[(1S)-1-(cyclohexylmethyl)-2-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-butenyl]amino]-2-oxoethyl]-3-(1-methylethyl)-2-oxo-3-piperidinyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323196-86-7 HCAPLUS

CN 1H-Azepine-1-acetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]hexahydro-3-[(methylsulfonyl)amino]-2-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323196-87-8 HCAPLUS

CN 1-Pyrrolidineacetamide, 3-amino- α -(cyclohexylmethyl)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-, monohydrochloride, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 323196-88-9 HCAPLUS

CN 1-Pyrrolidineacetamide, 3-[[[1,1'-biphenyl]-4-ylsulfonyl]amino]- α -(cyclohexylmethyl)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323196-89-0 HCAPLUS

CN 1-Pyrrolidineacetamide, α -(cyclohexylmethyl)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-3-[(4-propylphenyl)sulfonyl]amino]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323196-90-3 HCAPLUS


CN 1-Pyrrolidineacetamide, α -(cyclohexylmethyl)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-3-[(1-naphthalenylsulfonyl)amino]-2-oxo-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323196-91-4 HCAPLUS
 CN 1-Pyrrolidineacetamide, α -(cyclohexylmethyl)-N-[(1R)-1-
 [(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-
 benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-3-
 [[(phenylamino)carbonyl]amino]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323196-92-5 HCAPLUS
 CN 1-Pyrrolidineacetamide, α -(cyclohexylmethyl)-N-[(1R)-1-
 [(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-
 benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-3-[[3-
 methylphenyl)sulfonyl]amino]-2-oxo-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-93-6 HCAPLUS
 CN Boronic acid, [(1R)-1-[[[(2S)-3-cyclohexyl-2-[3-(1-methylethyl)-3-[[3-
 methylphenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-
 oxopropyl]amino]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323196-94-7 HCAPLUS

CN Carbamic acid, [1-[(1S)-2-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxo-1-phenylethyl]-3-(1-methylethyl)-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323196-95-8 HCAPLUS

CN 1-Pyrrolidineacetamide, 3-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo- α -phenyl-, monohydrochloride, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 323196-96-9 HCAPLUS
 CN 1-Pyrrolidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-3-[(methylsulfonyl)amino]-2-oxo-α-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-97-0 HCAPLUS
 CN 1-Pyrrolidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-α-phenyl-3-[[[4-propylphenyl)sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323196-98-1 HCAPLUS
 CN Carbamic acid, [1-[(1S)-1-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-

trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]carbonyl]-3-methylbutyl]-3-(1-methylethyl)-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323196-99-2 HCAPLUS

CN 1-Pyrrolidineacetamide, 3-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-α-(2-methylpropyl)-2-oxo-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 323197-00-8 HCAPLUS

CN 1-Pyrrolidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-α-(2-methylpropyl)-3-[(methylsulfonyl)amino]-2-oxo-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-01-9 HCAPLUS

CN 1-Pyrrolidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-α-(2-methylpropyl)-2-oxo-3-[[4-propylphenyl)sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-02-0 HCAPLUS

CN Pyrazinecarboxamide, N-[(1S)-1-[[[1-[(1S)-1-(cyclohexylmethyl)-2-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-butenyl]amino]-2-oxoethyl]-3-ethyl-2-oxo-3-pyrrolidinyl]amino]carbonyl]-2-methylpropyl]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323197-03-1 HCAPLUS

CN Carbamic acid, [1-[(1S)-1-(cyclohexylmethyl)-2-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxoethyl]-3-(1-methylethyl)-2-oxo-3-piperidinyl]-, (9CI) (CA INDEX NAME)

phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-04-2 HCAPLUS

CN Carbamic acid, [1-[(1S)-2-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxo-1-phenylethyl]-3-(1-methylethyl)-2-oxo-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-05-3 HCAPLUS

CN 1-Piperidineacetamide, 3-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-α-phenyl-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 323197-06-4 HCAPLUS
 CN Carbamic acid, [1-[(1S)-2-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxo-1-phenylethyl]-3-(1-methylethyl)-2-oxo-3-piperidinyl]-, methyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 323197-07-5 HCAPLUS
 CN 1-Piperidineacetamide, 3-(benzoylamino)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo- α -phenyl-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-08-6 HCAPLUS
 CN 1-Piperidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-3-[(methylsulfonyl)amino]-2-oxo- α -phenyl-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-09-7 HCAPLUS

CN 1-Piperidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-3-[[[(3-methylphenyl)sulfonyl]amino]-2-oxo- α -phenyl-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 85-46-1, 1-Naphthylsulfonyl chloride 98-88-4, Benzoyl chloride 103-71-9, Phenyl isocyanate, reactions 106-95-6, Allyl bromide, reactions 108-98-5, Thiophenol, reactions 124-63-0, Methanesulfonyl chloride 359-07-9 460-37-7, 3,3,3-Trifluoropropyl iodide 931-59-9, Phenylsulfenyl chloride 1149-26-4 1623-93-4, 4-Biphenylsulfonyl chloride 1730-25-2, Allylmagnesium bromide 1899-93-0 3182-79-4 4333-56-6, Cyclopropyl bromide 6009-07-0 13734-41-3 15028-39-4, L-Phenylglycine methyl ester hydrochloride 17193-39-4 18680-27-8 38329-34-9, L-Phenylglycine hydrochloride 42918-86-5 76347-13-2 84110-32-7 90084-27-8 119479-32-2 130653-09-7 146949-07-7 323197-58-6 323197-73-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease)


RN 85-46-1 HCAPLUS

CN 1-Naphthalenesulfonyl chloride (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 98-88-4 HCAPLUS


CN Benzoyl chloride (8CI, 9CI) (CA INDEX NAME)




RN 103-71-9 HCAPLUS
 CN Benzene, isocyanato- (9CI) (CA INDEX NAME)




RN 106-95-6 HCAPLUS
 CN 1-Propene, 3-bromo- (9CI) (CA INDEX NAME)




RN 108-98-5 HCAPLUS
 CN Benzenethiol (8CI, 9CI) (CA INDEX NAME)




RN 124-63-0 HCAPLUS
 CN Methanesulfonyl chloride (6CI, 8CI, 9CI) (CA INDEX NAME)




RN 359-07-9 HCAPLUS
 CN Ethane, 2-bromo-1,1-difluoro- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 460-37-7 HCAPLUS
 CN Propane, 1,1,1-trifluoro-3-iodo- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 931-59-9 HCAPLUS
 CN Benzenesulfonyl chloride (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 1149-26-4 HCAPLUS
 CN L-Valine, N-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).




RN 1623-93-4 HCAPLUS
 CN [1,1'-Biphenyl]-4-sulfonyl chloride (9CI) (CA INDEX NAME)




RN 1730-25-2 HCAPLUS
 CN Magnesium, bromo-2-propenyl- (9CI) (CA INDEX NAME)




RN 1899-93-0 HCAPLUS
 CN Benzenesulfonyl chloride, 3-methyl- (9CI) (CA INDEX NAME)



RN 3182-79-4 HCAPLUS
 CN Glycine, N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 4333-56-6 HCAPLUS
 CN Cyclopropane, bromo- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 6009-07-0 HCAPLUS
 CN Disulfide, chloro phenyl (8CI, 9CI) (CA INDEX NAME)

PhS-S-Cl


RN 13734-41-3 HCAPLUS
 CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 15028-39-4 HCAPLUS
 CN Benzeneacetic acid, α -amino-, methyl ester, hydrochloride,
 (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



● HCl

RN 17193-39-4 HCAPLUS
 CN Cyclohexanepropanoic acid, α -amino-, methyl ester, hydrochloride,
 (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 18680-27-8 HCAPLUS

CN Bicyclo[3.1.1]heptane-2,3-diol, 2,6,6-trimethyl-, (1S,2S,3R,5S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 38329-34-9 HCAPLUS

CN Benzeneacetic acid, α -amino-, hydrochloride, (α S)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 42918-86-5 HCAPLUS


CN Butanoic acid, 2-[[[(phenylmethoxy)carbonyl]amino]-, (2S)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry. Rotation (-).



RN 76347-13-2 HCAPLUS


CN 1,3,2-Dioxaborolane, 4,4,5,5-tetramethyl-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 84110-32-7 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole, 2-ethenylhexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 90084-27-8 HCAPLUS


CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[(1S)-1-chloro-2-(phenylmethoxy)ethyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 119479-32-2 HCAPLUS


CN 4-Pentenoic acid, 2-[[[(1,1-dimethylethoxy)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 130653-09-7 HCAPLUS
 CN 4,6-Methano-1,3,2-benzodioxaborole, 2-(1-chloroethenyl)hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)




RN 146949-07-7 HCAPLUS
 CN Benzenesulfonyl chloride, 4-propyl- (9CI) (CA INDEX NAME)




RN 323197-58-6 HCAPLUS
 CN L-Valine, N-(pyrazinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-73-5 HCAPLUS
 CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-trimethyl- α -2-propenyl-, (α R,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 66080-23-7P 66866-64-6P 70557-99-2P
 83622-42-8P 94242-86-1P 95656-94-3P
 126689-01-8P 131357-48-7P 131433-93-7P
 172096-96-7P 319009-74-0P 319009-76-2P
 319009-78-4P 319009-80-8P 319009-82-0P
 319009-90-0P 319009-92-2P 319009-94-4P
 319009-96-6P 319009-98-8P 319010-99-6P
 319011-02-4P 319011-08-0P 319011-10-4P
 319011-16-0P 319011-18-2P 319011-22-8P
 319011-25-1P 319011-27-3P 319011-29-5P
 323197-10-0P 323197-11-1P 323197-12-2P
 323197-13-3P 323197-14-4P 323197-15-5P
 323197-16-6P 323197-17-7P 323197-18-8P
 323197-19-9P 323197-20-2P 323197-21-3P
 323197-22-4P 323197-23-5P 323197-24-6P
 323197-25-7P 323197-26-8P 323197-27-9P
 323197-28-0P 323197-29-1P 323197-30-4P
 323197-31-5P 323197-32-6P 323197-33-7P
 323197-34-8P 323197-35-9P 323197-36-0P
 323197-37-1P 323197-38-2P 323197-39-3P
 323197-40-6P 323197-41-7P 323197-42-8P
 323197-43-9P 323197-44-0P 323197-45-1P
 323197-46-2P 323197-47-3P 323197-48-4P
 323197-74-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C
 virus NS3 protease)

RN 66080-23-7 HCAPLUS


CN 1,3,2-Dioxaborolane, 4,4,5,5-tetramethyl-2-[(phenylthio)methyl]- (9CI)
 (CA INDEX NAME)



RN 66866-64-6 HCAPLUS

CN 3-Oxazolidinecarboxylic acid, 4-(1-methylethyl)-5-oxo-, phenylmethyl
 ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 70557-99-2 HCAPLUS


CN 1,3,2-Dioxaborolane, 2-(iodomethyl)-4,4,5,5-tetramethyl- (9CI) (CA INDEX

NAME)




RN 83622-42-8 HCAPLUS

CN 1,3,2-Dioxaborolane, 2-(chloromethyl)-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 94242-86-1 HCAPLUS


CN 1,3,2-Dioxaborolane, 2-(1-chloroethyl)-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 95656-94-3 HCAPLUS


CN 3-Oxazolidinecarboxylic acid, 4-ethyl-5-oxo-, phenylmethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 126689-01-8 HCAPLUS


CN 1,3,2-Dioxaborolane, 2-cyclopropyl-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 131357-48-7 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[(1S)-1-chloro-3-butenyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 131433-93-7 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole, hexahydro-3a,5,5-trimethyl-2-(2-propenyl)-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172096-96-7 HCAPLUS

CN 3-Oxazolidinecarboxylic acid, 4-(1-methylethyl)-5-oxo-, 1,1-dimethylethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 319009-74-0 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-

trimethyl- α -[1-(phenylmethoxy)ethyl]-, hydrochloride,
 (α R,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 319009-76-2 HCAPLUS
 CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-trimethyl- α -[(phenylmethoxy)methyl]-, hydrochloride,
 (α R,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 319009-78-4 HCAPLUS
 CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-trimethyl- α -[(phenylthio)methyl]-, hydrochloride, (3aS,4S,6S,7aR)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 319009-80-8 HCAPLUS
 CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-trimethyl-α-[(phenyldithio)methyl]-, (3aS,4S,6S,7aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 319009-82-0 HCAPLUS
 CN 1,3,2-Dioxaborolane-2-methanamine, 4,4,5,5-tetramethyl-α-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)



RN 319009-90-0 HCAPLUS
 CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-trimethyl-α-2-propenyl-, hydrochloride, (αR,3aS,4S,6S,7aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 319009-92-2 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, α -ethylhexahydro-3a,5,5-trimethyl-, hydrochloride, (α R,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 319009-94-4 HCAPLUS

CN 1,3,2-Dioxaborolane-2-methanamine, α -cyclopropyl-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 319009-96-6 HCAPLUS


CN 1,3,2-Dioxaborolane-2-methanamine, α -(2,2-difluoroethyl)-4,4,5,5-tetramethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 319009-98-8 HCAPLUS
 CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, α -ethenylhexahydro-3a,5,5-trimethyl-, hydrochloride, (α R,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 319010-99-6 HCAPLUS
 CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[(1S)-1-chloropropyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 319011-02-4 HCAPLUS
 CN 1,3,2-Dioxaborolane, 2-(chlorocyclopropylmethyl)-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)




RN 319011-08-0 HCAPLUS

CN 1,3,2-Dioxaborolane, 2-[3,3-difluoro-1-(phenylthio)propyl]-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 319011-10-4 HCAPLUS


CN 1,3,2-Dioxaborolane, 2-(3,3-difluoro-1-iodopropyl)-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 319011-16-0 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole, hexahydro-3a,5,5-trimethyl-2-[1-(phenylmethoxy)ethyl]-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 319011-18-2 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[(1S)-1-chloro-2-(phenylmethoxy)propyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 319011-22-8 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[1-chloro-2-(phenylthio)ethyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 319011-25-1 HCAPLUS


CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[1-chloro-2-(phenyldithio)ethyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 319011-27-3 HCAPLUS


CN 1,3,2-Dioxaborolane, 4,4,5,5-tetramethyl-2-[4,4,4-trifluoro-1-(phenylthio)butyl]-(9CI) (CA INDEX NAME)




RN 319011-29-5 HCAPLUS
 CN 1,3,2-Dioxaborolane, 4,4,5,5-tetramethyl-2-(4,4,4-trifluoro-1-iodobutyl)-
 (9CI) (CA INDEX NAME)




RN 323197-10-0 HCAPLUS
 CN 3-Oxazolidinecarboxylic acid, 4-(1-methylethyl)-5-oxo-4-(2-propenyl)-,
 phenylmethyl ester (9CI) (CA INDEX NAME)



RN 323197-11-1 HCAPLUS
 CN 4-Pentenoic acid, 2-(1-methylethyl)-2-[[(phenylmethoxy) carbonyl] amino]-,
 methyl ester (9CI) (CA INDEX NAME)




RN 323197-12-2 HCAPLUS
 CN Valine, 2-(2-oxoethyl)-N-[(phenylmethoxy) carbonyl]-, methyl ester (9CI)
 (CA INDEX NAME)



RN 323197-13-3 HCAPLUS

CN 1-Pyrrolidineacetic acid, α -(cyclohexylmethyl)-3-(1-methylethyl)-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-14-4 HCAPLUS

CN 1-Pyrrolidineacetic acid, 3-amino- α -(cyclohexylmethyl)-3-(1-methylethyl)-2-oxo-, methyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-15-5 HCAPLUS

CN 1-Pyrrolidineacetic acid, α -(cyclohexylmethyl)-3-(1-methylethyl)-3-[[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-, methyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-16-6 HCAPLUS


CN 1-Pyrrolidineacetic acid, α-(cyclohexylmethyl)-3-(1-methylethyl)-3-
[[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-,
(αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323197-17-7 HCAPLUS

CN Norvaline, 5-hydroxy-2-(1-methylethyl)-N-[(phenylmethoxy)carbonyl]-,
methyl ester (9CI) (CA INDEX NAME)



RN 323197-18-8 HCAPLUS


CN Norvaline, 2-(1-methylethyl)-5-oxo-N-[(phenylmethoxy)carbonyl]-, methyl
ester (9CI) (CA INDEX NAME)



RN 323197-19-9 HCAPLUS

CN Cyclohexanepropanoic acid, α -[[4-(methoxycarbonyl)-5-methyl-4-
 [[(phenylmethoxy)carbonyl]amino]hexyl]amino]-, methyl ester, (α S)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-20-2 HCAPLUS

CN 1-Piperidineacetic acid, α -(cyclohexylmethyl)-3-(1-methylethyl)-2-
 oxo-3-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, (α S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-21-3 HCAPLUS

CN 1-Piperidineacetic acid, 3-amino- α -(cyclohexylmethyl)-3-(1-
 methylethyl)-2-oxo-, methyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-22-4 HCAPLUS

CN 1-Piperidineacetic acid, α -(cyclohexylmethyl)-3-(1-methylethyl)-3-
 [[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-,
 methyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-23-5 HCAPLUS


CN 1-Piperidineacetic acid, α -(cyclohexylmethyl)-3-(1-methylethyl)-3-
 [[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-,
 (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323197-24-6 HCAPLUS

CN Glycine, 4,5-didehydro-N-[(1,1-dimethylethoxy)carbonyl]norvalyl-N-2-
 propenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 323197-25-7 HCAPLUS

CN 1H-Azepine-1-acetic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2,3,4,7-tetrahydro-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 323197-26-8 HCAPLUS


CN 1H-Azepine-1-acetic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2,3,4,7-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



RN 323197-27-9 HCAPLUS

CN Carbamic acid, [1-[2-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxoethyl]hexahydro-2-oxo-1H-azepin-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323197-28-0 HCAPLUS

CN 1H-Azepine-1-acetamide, 3-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]hexahydro-2-

oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-29-1 HCAPLUS

CN 1-Pyrrolidineacetic acid, α-(cyclohexylmethyl)-3-(1-methylethyl)-2-oxo-3-[[(phenylmethoxy) carbonyl] amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-30-4 HCAPLUS

CN Carbamic acid, [1-[(1S)-1-(cyclohexylmethyl)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxoethyl]-3-(1-methylethyl)-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-31-5 HCAPLUS

CN 1-Pyrrolidineacetic acid, 3-(1-methylethyl)-2-oxo- α -phenyl-3-
[[(phenylmethoxy) carbonyl] amino]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-32-6 HCAPLUS


CN 1-Pyrrolidineacetic acid, 3-(1-methylethyl)- α -(2-methylpropyl)-2-oxo-
3-[[(phenylmethoxy) carbonyl] amino]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323197-33-7 HCAPLUS

CN 3-Oxazolidinecarboxylic acid, 4-ethyl-5-oxo-4-(2-propenyl)-, phenylmethyl
ester (9CI) (CA INDEX NAME)




RN 323197-34-8 HCAPLUS

CN 4-Pentenoic acid, 2-ethyl-2-[[(phenylmethoxy)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 323197-35-9 HCAPLUS


CN Butanoic acid, 2-ethyl-4-oxo-2-[[(phenylmethoxy)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 323197-36-0 HCAPLUS

CN 1-Pyrrolidineacetic acid, α -(cyclohexylmethyl)-3-ethyl-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-37-1 HCAPLUS

CN 1-Pyrrolidineacetic acid, 3-amino- α -(cyclohexylmethyl)-3-ethyl-2-oxo-, methyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 323197-38-2 HCAPLUS


CN 1-Pyrrolidineacetic acid, α -(cyclohexylmethyl)-3-ethyl-3-[[[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-, methyl ester, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323197-39-3 HCAPLUS
 CN 1-Pyrrolidineacetic acid, α -(cyclohexylmethyl)-3-ethyl-3-[[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 323197-40-6 HCAPLUS
 CN 3-Oxazolidinecarboxylic acid, 4-(1-methylethyl)-5-oxo-4-(2-propenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 323197-41-7 HCAPLUS
 CN 4-Pentenoic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 323197-42-8 HCAPLUS
 CN 4-Pentenoic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-2-(1-methylethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 323197-43-9 HCAPLUS

CN Norvaline, N-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-2-(1-methylethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 323197-44-0 HCAPLUS


CN Norvaline, N-[(1,1-dimethylethoxy)carbonyl]-2-(1-methylethyl)-5-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 323197-45-1 HCAPLUS


CN Benzeneacetic acid, α -[[4-[[[(1,1-dimethylethoxy)carbonyl]amino]-5-methyl-4-[(phenylmethoxy)carbonyl]hexyl]amino]-, methyl ester, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323197-46-2 HCAPLUS
 CN Benzeneacetic acid, α -[[4-carboxy-4-[[[1,1-dimethylethoxy)carbonyl]amino]-5-methylhexyl]amino]-, monomethyl ester, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323197-47-3 HCAPLUS
 CN 1-Piperidineacetic acid, 3-[[[1,1-dimethylethoxy)carbonyl]amino]-3-(1-methylethyl)-2-oxo- α -phenyl-, methyl ester, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 323197-48-4 HCAPLUS
 CN 1-Piperidineacetic acid, 3-[[[1,1-dimethylethoxy)carbonyl]amino]-3-(1-methylethyl)-2-oxo- α -phenyl-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-74-6 HCAPLUS
 CN 1-Pyrrolidineacetic acid, 3-(1-methylethyl)-2-oxo- α -phenyl-3-[[[phenylmethoxy)carbonyl]amino]-, methyl ester, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:607748 HCAPLUS

DOCUMENT NUMBER: 133:335259

TITLE: 1-Aminocyclopropaneboronic Acid: Synthesis and Incorporation into an Inhibitor of Hepatitis C Virus NS3 Protease

AUTHOR(S): Priestley, E. Scott; Decicco, Carl P.

CORPORATE SOURCE: Department of Chemical and Physical Sciences, DuPont Pharmaceuticals Company, Wilmington, DE, 19880, USA

SOURCE: Organic Letters (2000), 2(20), 3095-3097
CODEN: ORLEF7; ISSN: 1523-7060

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 133:335259


AB The previously unreported α,α -disubstituted 1-aminoboronate esters have potential utility in peptidomimetic design, particularly against serine protease targets. A concise synthesis of 1-aminocyclopropaneboronate pinanediol ester is reported, and a peptidyl derivative has modest affinity ($K_i = 1.6 \mu\text{M}$) for hepatitis C NS3 protease. Analogs with iso-Pr and cyclohexyl in place of cyclopropyl were also prepared and tested.

IT 274918-51-3, Boc-Asp(O-t-Bu)-Glu(O-t-Bu)-Val-Val-Pro-OH
RL: RCT (Reactant); RACT (Reactant or reagent)
(coupling with α,α -disubstituted 1-aminoboronate esters)


RN 274918-51-3 HCAPLUS

CN L-Proline, N-[(1,1-dimethylethoxy)carbonyl]-L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT **58644-54-5**, N-Cyclopropylformamide
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (dehydration with tosyl chloride and tributylamine)
 RN 58644-54-5 HCAPLUS
 CN Formamide, N-cyclopropyl- (9CI) (CA INDEX NAME)



IT **58644-53-4P**, Cyclopropyl isocyanide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (explosion hazard during reaction; preparation and lithiation followed by
 metathesis with triisopropyl borate in preparation of α,α -
 disubstituted 1-aminoboronate ester)
 RN 58644-53-4 HCAPLUS
 CN Cyclopropane, isocyano- (9CI) (CA INDEX NAME)




IT **5419-55-6**, Triisopropyl borate **18680-27-8**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (for preparation of α,α -disubstituted 1-aminoboronate esters)
 RN 5419-55-6 HCAPLUS
 CN Boric acid (H₃BO₃), tris(1-methylethyl) ester (9CI) (CA INDEX NAME)



RN 18680-27-8 HCAPLUS
 CN Bicyclo[3.1.1]heptane-2,3-diol, 2,6,6-trimethyl-, (1S,2S,3R,5S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).




IT **149885-80-3**, NS3 Protease
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)
 (hepatitis C virus; synthesis of α,α -disubstituted
 1-aminoboronate esters and incorporation into inhibitor of)
 RN 149885-80-3 HCAPLUS
 CN Proteinase, polyprotein-processing, NS3 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **598-45-8**, Isopropyl isocyanide **931-53-3**, Cyclohexyl
 isocyanide
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (lithiation followed by metathesis with triisopropyl borate in preparation
 of α,α -disubstituted 1-aminoboronate ester)
 RN 598-45-8 HCAPLUS
 CN Propane, 2-isocyano- (9CI) (CA INDEX NAME)




RN 931-53-3 HCAPLUS
 CN Cyclohexane, isocyano- (9CI) (CA INDEX NAME)



IT **303191-80-2P 303191-81-3P 303191-82-4P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); BIOL (Biological
 study); PREP (Preparation)
 (preparation and activity as inhibitor of hepatitis C NS3 protease)


RN 303191-80-2 HCAPLUS
 CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-[1-
 [(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-
 benzodioxaborol-2-yl]cyclopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 303191-81-3 HCAPLUS
 CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-[1-
 [(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-
 benzodioxaborol-2-yl]-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 303191-82-4 HCAPLUS
 CN L-Prolinamide, L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-[1-
 [(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-
 benzodioxaborol-2-yl]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 303191-71-1P 303191-72-2P 303191-73-3P



RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and conversion to amine hydrochloride using methanolic hydrogen chloride)

RN 303191-71-1 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole, hexahydro-2-(1-isocyanocyclopropyl)-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 303191-72-2 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole, hexahydro-2-(1-isocyano-1-methylethyl)-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 303191-73-3 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborole, hexahydro-2-(1-isocyanocyclohexyl)-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 303191-74-4P 303191-75-5P 303191-76-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and coupling with pentapeptide)

RN 303191-74-4 HCAPLUS

CN Cyclopropanamine, 1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 303191-75-5 HCAPLUS

CN 4,6-Methano-1,3,2-benzodioxaborol-2-methanamine, hexahydro- $\alpha,\alpha,3a,5,5$ -pentamethyl-, hydrochloride, (3aS,4S,6S,7aR)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 303191-76-6 HCAPLUS
 CN Cyclohexanamine, 1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

IT 303191-77-7P 303191-78-8P 303191-79-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and deprotection of)
 RN 303191-77-7 HCAPLUS
 CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]cyclopropyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 303191-78-8 HCAPLUS

CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-[1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-1-methylethyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 303191-79-9 HCAPLUS
CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-L- α -aspartyl-L- α -glutamyl-L-valyl-L-valyl-N-[1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]cyclohexyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



REFERENCE COUNT:

22

THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
23.75	33.05

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-2.77	-2.77

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:55:08 ON 04 JUN 2004